Advertisement
FLNA vs JAGX
Which Stock Would AI Choose? Filana Therapeutics (FLNA) vs. Jaguar Health (JAGX) Stock Comparison
Key Takeaways
- Both are speculative, small-cap biotech/pharma names trading on the Nasdaq with sub-$1-to-low-single-digit share prices and elevated volatility.
- FLNA is a clinical-stage developer of CNS (central nervous system) therapies that has faced an FDA clinical hold and a Nasdaq listing-compliance notice.
- JAGX is a commercial-stage gastrointestinal (GI) drug developer whose recent revenue surged on a licensing deal and debt restructuring.
- FLNA's relative performance has been pressured by regulatory uncertainty, while JAGX has benefited from a tangible revenue catalyst but carries dilution risk from reverse stock splits.
- Investor interest in both names is driven by binary catalysts rather than steady fundamentals.
Introduction
This stock comparison examines two small-cap healthcare companies that sit on opposite ends of the development-to-commercialization spectrum. FLNA (Filana Therapeutics) is a clinical-stage biotechnology firm pursuing central nervous system treatments, while JAGX (Jaguar Health) is a commercial-stage pharmaceutical company with an FDA-approved product and emerging licensing income. Traders and investors who follow speculative, catalyst-driven names in the healthcare sector may find this comparison relevant, as both stocks carry the potential for sharp moves tied to regulatory, financing, and clinical developments rather than conventional earnings growth.
FLNA Overview and Recent Performance
FLNA, formerly known as Cassava Sciences, rebranded to Filana Therapeutics in March 2026 to reflect its strategic focus on modulating the filamin A protein for central nervous system disorders, including tuberous sclerosis complex (TSC)-related epilepsy. Its lead program, simufilam, is an investigational oral therapy, complemented by an early-stage diagnostic candidate, SavaDx.
Recent market activity has been challenging for FLNA. The company has been addressing an FDA clinical hold on simufilam, which stemmed from a request for additional information issued in late 2025. In recent weeks, FLNA also received a Nasdaq non-compliance notice after trading below the $1.00 minimum bid threshold, with a grace period extending into early 2027 to regain compliance. These developments have weighed on sentiment, pushing the stock toward the lower end of its 52-week range. On the positive side, FLNA reported a narrowing net loss in recent quarters and holds a meaningful cash balance, and a small number of sell-side analysts maintain a "Buy" rating with price targets well above current levels.
JAGX Overview and Recent Performance
JAGX (Jaguar Health) develops plant-derived prescription medicines for gastrointestinal conditions. Its flagship product, Mytesi (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy, and it also markets Canalevia-CA1 for chemotherapy-induced diarrhea in dogs.
Recent performance has been characterized by notable catalysts and persistent volatility. JAGX completed a debt and royalty restructuring in recent months, reducing obligations and extinguishing outstanding warrants, which strengthened its balance sheet. The company also reported a sharp year-over-year revenue increase driven by a U.S. licensing agreement for Mytesi and Canalevia-CA1 that included an upfront payment. However, the stock has experienced significant swings, and Jaguar has executed multiple reverse stock splits to maintain Nasdaq listing compliance, signaling ongoing dilution and capital-structure concerns. These mixed signals have kept JAGX's relative performance uneven even amid improving revenue.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that trade thousands of different tickers across diverse strategies, timeframes, and risk profiles. Because market conditions change constantly, only a select group of the best-performing and most suitable bots is featured in the curated Trending AI Robots section. These bots differ in trading style, holding periods, performance statistics, and the sets of tickers they monitor, allowing traders to find an approach aligned with their own objectives. Whether you are evaluating a speculative healthcare name like those in this comparison or a broader portfolio, exploring the Trending AI Robots page can help you identify AI-driven tools suited to current market conditions.
Head-to-Head Comparison
The two companies differ sharply in business model and market positioning. FLNA is pre-revenue and clinical-stage, meaning its value is tied almost entirely to the outcome of its simufilam program and resolution of the FDA clinical hold. Its growth drivers are binary: a successful regulatory path could re-rate the stock materially, while continued setbacks would prolong downside pressure. JAGX, by contrast, generates commercial and licensing revenue and has taken steps to de-lever its balance sheet, giving it more concrete, near-term financial catalysts.
Risk profiles also diverge. FLNA's primary risks are regulatory and cash-burn related, compounded by Nasdaq listing pressure. JAGX's risks center on dilution, frequent reverse stock splits, and heavy reliance on a single product franchise and licensing partner. Sector exposure is similar — both are speculative healthcare names — but JAGX offers modest diversification through animal-health revenue. In terms of momentum, JAGX has shown episodic spikes around catalysts, while FLNA has trended lower amid an unresolved clinical hold.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean slightly toward JAGX in the current environment. The company's revenue inflection from a completed licensing deal and its balance-sheet restructuring represent tangible, measurable catalysts, whereas FLNA remains anchored by an unresolved FDA clinical hold and a sub-$1 share price. That said, neither stock exhibits clean trend consistency, and JAGX's history of reverse stock splits introduces structural instability that weighs on any assessment. A probabilistic framework would therefore describe the edge to JAGX as modest and conditional, with both names carrying elevated, catalyst-dependent risk that makes them unsuitable as low-volatility holdings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FLNA is a Hold and JAGX is a Hold.
FLNA's RSI Oscillator leaves overbought zone
The 10-day RSI Oscillator for FLNA moved out of overbought territory on September 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In 24 of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FLNA as a result. In 80 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FLNA turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
FLNA moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FLNA crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
FLNA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for FLNA entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +23.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where FLNA advanced for three days, in 191 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.648) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.320) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. FLNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
JAGX's RSI Indicator leaves overbought zone
The 10-day RSI Indicator for JAGX moved out of overbought territory on September 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 13 instances where the indicator moved out of the overbought zone. In 13 of the 13 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JAGX as a result. In 65 of 68 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
JAGX moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
JAGX broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JAGX entered a downward trend on September 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for JAGX just turned positive on October 06, 2026. Looking at past instances where JAGX's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Following a +53.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAGX advanced for three days, in 140 of 174 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.473) is normal, around the industry mean (26.782). P/E Ratio (0.004) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.003) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. JAGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JAGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FLNA | JAGX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 96 | 96 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 85 | 95 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JAGX's Valuation (8) in the Pharmaceuticals Generic industry is in the same range as FLNA (32) in the Pharmaceuticals Other industry. This means that JAGX’s stock grew similarly to FLNA’s over the last 12 months.
JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as FLNA (100) in the Pharmaceuticals Other industry. This means that JAGX’s stock grew similarly to FLNA’s over the last 12 months.
FLNA's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that FLNA’s stock grew similarly to JAGX’s over the last 12 months.
FLNA's Price Growth Rating (85) in the Pharmaceuticals Other industry is in the same range as JAGX (95) in the Pharmaceuticals Generic industry. This means that FLNA’s stock grew similarly to JAGX’s over the last 12 months.
FLNA's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that FLNA’s stock grew similarly to JAGX’s over the last 12 months.
| FLNA | JAGX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Advances ODDS (%) | 16 days ago 80% | 9 days ago 80% |
| Declines ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FLNA’s FA Score shows that 1 FA rating(s) are green while JAGX’s FA Score has 1 green FA rating(s).
- FLNA’s FA Score: 1 green, 4 red.
- JAGX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FLNA’s TA Score shows that 2 TA indicator(s) are bullish while JAGX’s TA Score has 3 bullish TA indicator(s).
- FLNA’s TA Score: 2 bullish, 8 bearish.
- JAGX’s TA Score: 3 bullish, 6 bearish.
Price Growth
FLNA (@Biotechnology) experienced а -15.03% price change this week, while JAGX (@Biotechnology) price change was -25.98% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.22%. For the same industry, the average monthly price growth was -17.98%, and the average quarterly price growth was -18.86%.
Reported Earning Dates
FLNA is expected to report earnings on Nov 11, 2026.
JAGX is expected to report earnings on Nov 18, 2026.
Industries' Descriptions
@Biotechnology (-7.22% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
FLNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, FLNA has been loosely correlated with ALT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FLNA jumps, then ALT could also see price increases.
| Ticker / NAME | Correlation To FLNA | 1D Price Change % | ||
|---|---|---|---|---|
| FLNA | 100% | -3.39% | ||
| ALT - FLNA | 43% Loosely correlated | -5.08% | ||
| JAGX - FLNA | 42% Loosely correlated | -10.34% | ||
| EDIT - FLNA | 41% Loosely correlated | -11.09% | ||
| VYGR - FLNA | 41% Loosely correlated | -5.29% | ||
| RCKT - FLNA | 40% Loosely correlated | -7.26% | ||
More | ||||